Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 6;10(9):1990.
doi: 10.3390/jcm10091990.

Platelet Transfusion-Insights from Current Practice to Future Development

Annina Capraru  1 , Katarzyna Aleksandra Jalowiec  1 , Cesare Medri  1 , Michael Daskalakis  1   2 , Sacha Sergio Zeerleder  1   2   3 , Behrouz Mansouri Taleghani  1
Affiliations
Review

Platelet Transfusion-Insights from Current Practice to Future Development

Annina Capraru et al. J Clin Med. .

Abstract

Since the late sixties, therapeutic or prophylactic platelet transfusion has been used to relieve hemorrhagic complications of patients with, e.g., thrombocytopenia, platelet dysfunction, and injuries, and is an essential part of the supportive care in high dose chemotherapy. Current and upcoming advances will significantly affect present standards. We focus on specific issues, including the comparison of buffy-coat (BPC) and apheresis platelet concentrates (APC); plasma additive solutions (PAS); further measures for improvement of platelet storage quality; pathogen inactivation; and cold storage of platelets. The objective of this article is to give insights from current practice to future development on platelet transfusion, focusing on these selected issues, which have a potentially major impact on forthcoming guidelines.

Keywords: cold stored platelet concentrates; platelet additive solutions; platelet pathogen inactivation/reduction; platelet transfusion alternatives; platelet transfusion guidelines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Duke W.W. The relation of blood platelets to hemorrhagic disease: Description of a method for determining the bleeding time and coagulation time and report of three cases of hemorrhagic disease relieved by transfusion. JAMA. 1910;55:1185–1192. doi: 10.1001/jama.1910.04330140029009. - DOI
    1. Hersh E.M., Bodey G.P., Nies B.A., Freireich E. Causes of death in acute leukemia: A ten-year study of 414 patients from 1954–1963. JAMA. 1965;193:105–109. doi: 10.1001/jama.1965.03090020019005. - DOI - PubMed
    1. Han T., Stutzman L., Cohen E., Kim U. Effect of platelet transfusion on hemorrhage in patients with acute leukemia: An autopsy study. Cancer. 1966;19:1937–1942. doi: 10.1002/1097-0142(196612)19:12<1937::AID-CNCR2820191221>3.0.CO;2-G. - DOI - PubMed
    1. Schiffer C.A., Bohlke K., Delaney M., Hume H., Magdalinski A.J., McCullough J.J., Omel J.L., Rainey J.M., Rebulla P., Rowley S.D., et al. Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 2018;36:283–299. doi: 10.1200/JCO.2017.76.1734. - DOI - PubMed
    1. Estcourt L.J., Birchall J., Allard S., Bassey S.J., Hersey P., Kerr J.P., Mumford A.D., Stanworth S.J., Tinegate H. British Committee for Standards in Haematology: Guidelines for the use of platelet transfusions. Br. J. Haematol. 2017;176:365–394. doi: 10.1111/bjh.14423. - DOI - PubMed